Novartis will present data from five key abstracts evaluating the highly selective oral Bruton's tyrosine kinase inhibitor (BTKi) Rhapsido®? (remibrutinib) in chronic spontaneous urticaria (CSU) and as an investigational therapy for peanut allergy at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA, from February 27 to March 2, 2026. These presentations provide more evidence on the use of Rhapsido in CSU, as well as its potential in other indications and highlight Novartis commitment to addressing unmet needs in patients with immune-mediated diseases.

Plans are in progress to begin the Phase III program in FA in 2026. In addition to FA, remibrutinib is in clinical development for chronic inducible urticaria (CIndU) and dine submission for remibrutinib in symptomatic dermographism, the most prevalent type of CIndU, was completed in fourth quarter 2025. Additionally, positive topline results were announced for the remaining two arms of the CIndU Phase III RemIND trial.

Building on legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, the company's committed to shaping what's next in Immunology.